In a study published in PLOS One last month, the researchers compared results from the BGISEQ-500 and the Illumina HiSeq X Ten for tumor and germline samples from three patients.
BGI has ordered 10 Sequel systems to meet long-read sequencing demand for bacterial, plant, and animal de novo, transcriptome, and epigenomics sequencing.
The Chinese government has implemented clearer regulatory guidance for genomic tests and invested in both clinical testing and research, spurring growth.
Along with sequencing and resequencing on orphan crop plants, the team is providing professional development to spur genomics-assisted plant breeding in Africa.
Among the firms reporting, BGI talked about plans to cut down the time and cost of its WGS service, and Invitae's CEO made a surprising proclamation about genetic testing.
The firms plan to integrate Curetis' Unyvero sample prep system and MGI's NGS to create a microbial pathogens and antibiotic resistance detection workflow.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The partners plan to apply genomics to traditional Chinese medicine.
The researchers said that better diagnostics are needed to distinguish between false preterm labor and true preterm labor to prevent unnecessary treatment.
The partners are initially planning to make searchable whole-genome data and EMRs from more than 1,000 rheumatoid arthritis patients accessible to trial developers.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.